RCT: The effect of azithromycin on structural lung disease in infants with cystic fibrosis.
7 Jun, 2022 | 11:29h | UTCThe effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)